Raymond James Financial Inc Summit Therapeutics Inc. Transaction History
Raymond James Financial Inc
- $280 Billion
- Q2 2025
A detailed history of Raymond James Financial Inc transactions in Summit Therapeutics Inc. stock. As of the latest transaction made, Raymond James Financial Inc holds 11,692 shares of SMMT stock, worth $204,843. This represents 0.0% of its overall portfolio holdings.
Number of Shares
11,692Holding current value
$204,843% of portfolio
0.0%Shares
1 transactions
Others Institutions Holding SMMT
# of Institutions
270Shares Held
90.5MCall Options Held
4.71MPut Options Held
3.17M-
Baker Bros. Advisors LP New York, NY33.7MShares$591 Million7.27% of portfolio
-
Vanguard Group Inc Valley Forge, PA11.4MShares$199 Million0.0% of portfolio
-
Black Rock Inc. New York, NY7.9MShares$138 Million0.0% of portfolio
-
State Street Corp Boston, MA4.02MShares$70.4 Million0.0% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD3.91MShares$68.4 Million0.01% of portfolio
About Summit Therapeutics Inc.
- Ticker SMMT
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 201,215,008
- Market Cap $3.53B
- Description
- Summit Therapeutics Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat infectious diseases in the United States and Latin America. It conducts clinical programs focusing on Clostridioides difficile infection (CDI). The company's lead product candidate is ridinilazole, an orally administered small molecu...